Literature DB >> 21767591

Evaluation of the immunogenicity and the protective efficacy of a novel identified immunogenic protein, SsPepO, of Streptococcus suis serotype 2.

Jinquan Li1, Jin Xia, Chen Tan, Yang Zhou, Yan Wang, Chengkun Zheng, Huanchun Chen, Weicheng Bei.   

Abstract

Streptococcus suis serotype 2 (S. suis 2) is an important porcine and human pathogen. Some proteins secreted by S. suis 2 are thought to play important roles in the pathogenesis of this organism and in its induced immune response. SsPepO has been previously identified as a secretary immunogenic protein using immunoproteomic techniques. In this study, we confirmed that the sequence of this protein is highly conserved in S. suis 2 and compared it with its homologues in other pathogens. To test the protective efficacy of SsPepO in animal models, the recombinant SsPepO protein was used to immunize mice and pigs. The results demonstrated that it could elicit a strong humoral antibody response and confer significant protection against challenge with a lethal dose of S. suis 2 in mice and pig models. In addition, the antisera against rSsPepO could efficiently inhibit bacterial growth in a whole blood assay and conferred significant protection against S. suis 2 infection in passive immunization experiments. Our findings suggest that SsPepO plays an important role in the pathogenesis of S. suis 2 and would be a promising subunit vaccine candidate.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21767591     DOI: 10.1016/j.vaccine.2011.07.010

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Predominance of Streptococcus suis ST1 and ST7 in human cases in China, and detection of a novel sequence type, ST658.

Authors:  Yang Zhou; Xingxing Dong; Zhiwei Li; Geng Zou; Li Lin; Xiaohong Wang; Huanchun Chen; Robin B Gasser; Jinquan Li
Journal:  Virulence       Date:  2016-09-30       Impact factor: 5.882

2.  Endopeptidase PepO Regulates the SpeB Cysteine Protease and Is Essential for the Virulence of Invasive M1T1 Streptococcus pyogenes.

Authors:  Stephan Brouwer; Amanda J Cork; Cheryl-Lynn Y Ong; Timothy C Barnett; Nicholas P West; Kevin S McIver; Mark J Walker
Journal:  J Bacteriol       Date:  2018-03-26       Impact factor: 3.490

3.  Adhesion protein ApfA of Actinobacillus pleuropneumoniae is required for pathogenesis and is a potential target for vaccine development.

Authors:  Yang Zhou; Lu Li; Zhaohui Chen; Hong Yuan; Huanchun Chen; Rui Zhou
Journal:  Clin Vaccine Immunol       Date:  2012-12-26

Review 4.  Streptococcus suis infection: an emerging/reemerging challenge of bacterial infectious diseases?

Authors:  Youjun Feng; Huimin Zhang; Zuowei Wu; Shihua Wang; Min Cao; Dan Hu; Changjun Wang
Journal:  Virulence       Date:  2014-03-25       Impact factor: 5.882

5.  Draft Genome Sequence of Hypervirulent and Vaccine Candidate Streptococcus suis Strain SC19.

Authors:  Lin Teng; Xingxing Dong; Yang Zhou; Zhiwei Li; Limei Deng; Huanchun Chen; Xiaohong Wang; Jinquan Li
Journal:  Genome Announc       Date:  2017-01-19

6.  Vaccination with the immunoglobulin M-degrading enzyme of Streptococcus suis, Ide Ssuis, leads to protection against a highly virulent serotype 9 strain.

Authors:  Karoline Rieckmann; Anna Seydel; Kristin Klose; Gottfried Alber; Christoph G Baums; Nicole Schütze
Journal:  Vaccine X       Date:  2019-10-10

7.  Proteomic and Bioinformatic Analysis of Streptococcus suis Human Isolates: Combined Prediction of Potential Vaccine Candidates.

Authors:  Esther Prados de la Torre; Antonio Rodríguez-Franco; Manuel J Rodríguez-Ortega
Journal:  Vaccines (Basel)       Date:  2020-04-18

8.  Salmonella enterica serovar Choleraesuis vector delivering SaoA antigen confers protection against Streptococcus suis serotypes 2 and 7 in mice and pigs.

Authors:  Yu-An Li; Zhenying Ji; Xiaobo Wang; Shifeng Wang; Huoying Shi
Journal:  Vet Res       Date:  2017-12-21       Impact factor: 3.683

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.